As recent clinical data revealed that metastases are an independent prognostic factor for overall survival (OS) in patients with SCLC treated with immune checkpoint blockade (25), we next evaluated whether ANG-2 blockade improves therapeutic outcome in SCLC. The gene discussed is ANGPT2; the disease is small cell lung carcinoma.